LYEL at a glance
Lyell Immunopharma Inc (LYEL, SEC CIK 1806952) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lyell Immunopharma Inc (LYEL) reported revenue of $36,000 (down 41.0% from FY2024) and a net loss of $274.4 million. Diluted EPS was -$16.06.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Lyell Immunopharma Inc (LYEL) shares worth $34.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Lee Gary K. on November 10, 2026 of 129 shares at $15.93 per share.
- In the last 90 days, LYEL insiders reported 2 open-market purchases ($50.0M) and 6 open-market sales ($29K) on Form 4, a net purchase of $50.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $36K
- −41.0% vs prior year
- Insiders · 90 days
- 2 buys · 6 sells
- Net +$50.0M
- 13F holders
- 22 funds
- $34.8M · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added trade-policy risk: April 2026 tariffs up to 100% on certain imported pharmaceuticals, APIs and key starting materials
- Most materially updated capital risk: November 2026 Securities Purchase Agreement is the only committed external funding source
- Regulatory compliance risk: cGMP or cGTP failures could trigger clinical holds, production suspension, recalls or approval withdrawal
- Near-term trial risk: Competitor liso-cel and axi-cel availability may reduce enrollment in the PiNACLE-H2H trial
- Financial dilution risk: ICT may receive up to 1.85 million additional shares, including 1.1 million issued in July 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or product sales
- Operating loss $48.3M vs $37.3M YoY, net loss $45.5M vs $38.8M
- R&D expense $40.9M vs $28.2M, driven by increased clinical trial activity
- Cash, equivalents and marketable securities $194.0M; operating cash outflow $107.0M
- Guidance: liquidity sufficient for at least 12 months; additional capital needed, with clinical and manufacturing costs rising
AI summary of the LYEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release Exhibit 99.1 contains the detailed results and management commentary
Item EX-99.1: Item EX-99.1
- Ronde-cel efficacy remained strong: 91% overall response and 77% complete response among 44 evaluable 3L+ patients
- Durability signals favorable, with complete response rates estimated at 92% at six months and 75% at 12 months
Item 3.02: Unregistered Sales of Equity Securities
- $80.0 million gross proceeds targeted through private placement of 7,428,040 common shares
- $10.77 per-share issuance price, implying potential dilution for existing shareholders
Item 8.01: Other Events
- LYL273 technology transfer completed at Lyell’s LyFE Manufacturing Facility in Bothell, Washington
- Phase 1/2 trial timeline updated for metastatic colorectal cancer
Item EX-99.1: Item EX-99.1
- LyFE manufacturing transfer completed after FDA review, advancing LYL273 toward scalable clinical supply
- Improved manufacturing process and analytical methods target higher performance and capacity
AI summaries of LYEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LYEL
Don't miss the next LYEL filing
- Alerts as it files. A push when LYEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LYEL, by share count.
- Ask anything. An AI agent that reads every LYEL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lee Gary K. | Sell | Nov 10, 2026 | 129 | $15.93 |
| Bulis Veronica Sanchez | Sell | Nov 10, 2026 | 416 | $15.93 |
| Seely Lynn | Sell | Nov 10, 2026 | 545 | $15.93 |
| Hill Stephen J. | Sell | Nov 10, 2026 | 88 | $15.93 |
| ARCH Venture Partners IX, LLC | Buy | Nov 4, 2026 | 2,321,262 | $10.77 |
| ARCH Venture Fund XIII, L.P. | Buy | Nov 4, 2026 | 2,321,262 | $10.77 |
| Aguirre Jarrad Mattieu | Sell | Oct 12, 2026 | 422 | $8.63 |
| Aguirre Jarrad Mattieu | A | Sep 10, 2026 | 47,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $130K | $61K | $36K |
| Operating Income | - | -$358.8M | -$269.4M |
| Net Income | -$234.6M | -$343.0M | -$274.4M |
| Op. Margin | - | -588123.0% | -748344.4% |
| Net Margin | -180486.2% | -562285.2% | -762355.6% |
| Balance Sheet | |||
| Total Assets | - | $490.9M | $340.1M |
| Equity | - | $382.8M | $248.2M |
| ROE | - | -89.6% | -110.6% |
| Per Share | |||
| EPS | $-0.93 | $-1.31 | $-16.06 |
| Cash Flow | |||
| Operating CF | - | -$162.4M | -$150.0M |
| CapEx | $2.7M | $464K | $780K |
Source: XBRL data in Lyell Immunopharma Inc (LYEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate LYEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $34.8M |
| Q2 2026 | 22 | $43.0M |
| Q1 2026 | 20 | $51.6M |
| Q4 2025 | 21 | $66.7M |
| Q3 2025 | 17 | $32.4M |
| Q2 2025 | 20 | $15.4M |
- Two Sigma Investments+115.2K (+218%)
- Citadel Advisors LLC+88.0K (+471%)
- BlackRock+74.7K (+10%)
- Renaissance Technologies LLC+58.9K (+45%)
- Morgan Stanley+52.4K (+141%)
- Millennium Management−226.4K (-62%)
- Vanguard Capital Management LLC−37.9K (-5%)
- Dimensional Fund Advisors−21.9K (-32%)
- Northern Trust−19.8K (-17%)
- Wells Fargo & Co−6.2K (-78%)
- AQR Capital Management+345.9K
- FMR LLC (Fidelity)−2.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LYEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LYEL SEC filings: frequently asked questions
Are LYEL insiders buying or selling?
In the last 90 days, Lyell Immunopharma Inc (LYEL) officers, directors and 10% owners reported 2 open-market purchases worth $50.0 million by 2 insiders and 6 open-market sales worth $28,757 by 6 insiders on Form 4, a net purchase of $50.0 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LYEL stock?
As of September 30, 2026, the largest Lyell Immunopharma Inc (LYEL) holders among the 13F filers tracked by SignalX were BlackRock ($7.8 million), Vanguard Capital Management LLC ($7.3 million), AQR Capital Management ($3.4 million), Alphabet Inc ($2.9 million), State Street Corp ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LYEL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lyell Immunopharma Inc (LYEL) reported revenue of $36,000 (down 41.0% from FY2024) and a net loss of $274.4 million. Diluted EPS was -$16.06. The figures come from the XBRL data in the 10-K.
What did LYEL report in its latest 8-K?
Lyell Immunopharma Inc (LYEL) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest LYEL SEC filings?
Lyell Immunopharma Inc (LYEL) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.
What is LYEL's SEC CIK number?
Lyell Immunopharma Inc (LYEL)'s SEC Central Index Key (CIK) is 1806952. EDGAR lists every LYEL filing under that number.
Ask anything about LYEL
The research agent reads LYEL's filings, financials, insider trades and 13F holders, then answers with sources.